Nanodigmbio Biotechnology

Nanodigmbio believes in Nano Trans More, dedicated to creating more value and serving diagnosis in the field of targeted sequencing. Nanodigmbio is committed to providing specialized and high-quality products and ready-for-use solutions for academic institutions, medical institutions, NGS industrial companies etc.Nanodigmbio has complete series of products in targeted sequencing, including kinds of library preparation kits and liquid phase hybridization reagents, compatible with MGI and illumina platforms. Nanodigmbio provides optimized panels for applications in precision medicine and research, including exome research panel, pan-cancer research panel, hemooncology research panel and respirovirus research panel, and excellent customized panel validated by NGS. Nanodimbio owns...

Next generation sequencing,dna/rna library construction,target capture for ngs,single-cell whole-genome amplification,methyl cap,dna cap,and rna cap

Nanodigmbio biotechnology operates in the Biotechnology research industry.

Nanodigmbio biotechnology's revenue is 11m - 100m

Nanodigmbio biotechnology has 11 - 50 employees.